Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous rituximab plus intravenous bendamustine in very elderly or medically unfit elderly patients with aggressive CD20-positive B-cell lymphoma
2010-024004-98Phase 2Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and Mecbentu in mature B-cell lymphoma, sponsored by Universitätsmedizin Göttingen. Primary endpoints: 2-year progression-free survival, therapy-associated deaths and 3 more. Started Oct 2011; status: completed.
02
Drugs
rituximabMecbentu
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2010-024004-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024004-98.